Nova Precision AI

Bringing Global Expertise in Precision Oncology to Your Treatment

[Wafik S. El-Deiry, MD, PhD, FACP @weldeiry]

Register for the 2026 WIN Symposium in Precision Oncology

https://t.co/r7kEcHasFH

[Toni Choueiri, MD @DrChoueiri]

🚨 Results from #LITESPARK022 (#LS022) are out in @NEJM!

1/This phase III trial evaluated whether adding the HIF-2α inhibitor Belzutifan (BEL) to adjuvant pembrolizumab (PEMBRO) could improve outcomes for patients with resected clear-cell RCC at increased risk for recurrence.

https://t.co/1BLAercj3p
@oncoalert @asco @myESMO

[Nova Precision AI @NovaPrecisionAI]

Congratulations to @SewantiLimaye on receiving the "Visionary Clinician Award in Precision Medicine"
#PrecisionMedicine #HealthcareLeadership #ClinicalExcellence #InnovationInHealthcare #Earlydetection #Precisiononcology #Novaprecisionai
@iitbombay @WIN_Consortium @AACR @myESMO

[Nova Precision AI @NovaPrecisionAI]

#CARTCellTherapy #CellTherapy #SolidTumors #CancerImmunotherapy #Oncology #CancerResearch #PrecisionMedicine #Genomics #Immunotherapy #GastricCancer #TranslationalMedicine #Biotechnology #LifeSciences #MedicalInnovation #CancerTreatment

[Nova Precision AI @NovaPrecisionAI]

#WorldCancerDay | #UnitedByUnique
Cancer challenges more than the body it tests families, systems, and equity.
We believe in
🌍 Access beyond geography
🧬 Precision over guesswork
🤝 Patients as partners
💙 Science with compassion
Awareness isn’t enough.
#WorldCancerDay2026

[Oscar Tahuahua @OscarTahuahua]

More evidence that #immunotherapy works better in the morning.

In a prospective, randomized phase III trial, giving first-line chemo-immunotherapy earlier in the day (<15:00) nearly doubled PFS (11.3 vs 5.7 mo, HR 0.40) and improved OS (28.0 vs 16.8 mo; HR 0.42) in advanced NSCLC.

More effective, no added cost and easy to implement.
Likely reflects circadian immune rhythms with greater CD8⁺ activation and less T-cell exhaustion.
https://t.co/q4JrFU4yws @OncoAlert

[Razelle Kurzrock, MD @Dr_R_Kurzrock]

ADCs are like Trojan horses. 👉🚨🔥They exploit cell surface receptors to internalise chemo payloads into cancer cells. Next generation therapies. Enhertu shows responses in leptomeningeal disease. 🎯
https://t.co/P3Es65UqNw

[Balazs Halmos @BalazsHalmosMD]

If you need guidance on all the complexities on how to treat patients with NSCLC with or without driver alterations then:

Who you gonna ask? Ask ASCO of course!

Updated living @ASCO guidelines are out and they come along with
☑️slides
☑️podcast
☑️recommendations table
☑️algorithm
☑️pocket card
☑️and patient information!
These guidelines have everything- check them out!

Amazing work by team leads- @LudaBazhenovaMD @Sonampuri Natasha Leighl, Josh Reuss and ASCO champion, Nofisat Ismaila!

[Sewanti Limaye 🇮🇳🇺🇸 @SewantiLimaye]

Mesmerising talk by @VivekSubbiah @AdvancingPM #Philadelphia @WIN_Consortium @weldeiry @Dr_R_Kurzrock Speaking on “Charting the Future of Cancer Care” he appealed for a special attention to #TumorAgnosticApproach with special biomarkers and #AccelaratedDrugDevelopment !

[Wafik S. El-Deiry, MD, PhD, FACP @weldeiry]

Great to see Dr. Sewanti Limaye @SewantiLimaye, Dr. Jake Scott @CancerConnector @ClevelandClinic, colleagues from @BrownMedicine, including Dr. Bene Carneiro @bcarneiro7, @SenduraiMani, @LiangChengMD, Matt Hadfield, Dr. @LiaTsimberidou from @MDAndersonNews, and Milan Radovich @carisls at 2025 @WIN_Consortium Symposium at Philly Convention Center.

[sabine hazan md @SabinehazanMD]

Bravo @SewantiLimaye on a brilliant talk that puts Precision Medicine at the forefront for the patients by the patients. With @LiangChengMD @Dr_R_Kurzrock @weldeiry @LiaTsimberidou @SenduraiMani @bcarneiro7 @pashtoonkasi at @WIN_Consortium

[sabine hazan md @SabinehazanMD]

So great meeting some of the Women of @WIN_Consortium @SewantiLimaye @LiaTsimberidou @Dr_R_Kurzrock Dr Sholler, Dr Lilian Siu…

[JIPO Editors @JIPOEditors]

Limaye et al. explore "Exceptional Response to Immunotherapy-based Treatment in compound EGFR-Mutated Oligometastatic Pulmonary Sarcomatoid Carcinoma" in a new #JIPO https://t.co/I7DRayXPFX #immunotherapy #precisiononcology @DoubaZain @ANaingMD @OncologyNetwork @SewantiLimaye

[Sewanti Limaye 🇮🇳🇺🇸 @SewantiLimaye]

Great Keynote address by Nobel Laureate Prof. William Kaelin speaking on Drugging the Undruggable at the #APM Advancing Precision Medicine meeting #Philadelphia . Privileged to be here as a faculty @WIN_Consortium @weldeiry @Dr_R_Kurzrock #PrecisionOncology

[Sewanti Limaye 🇮🇳🇺🇸 @SewantiLimaye]

Great talks and panel - Dr David Spetzer from @CarisLife on #multiomics and #ClinicalDecisionSupport; Dr Keith Flaherty on #NextGenerationPrecisionOncology at @AdvancingPM #Philadelphia @WIN_Consortium @weldeiry @Dr_R_Kurzrock Dr Jeff Elton @PrecisionRx @ConcertAI

[Sewanti Limaye 🇮🇳🇺🇸 @SewantiLimaye]

Contributing to #LungCancerScreening 1000 high risk subjects, AI, LDCT, Liquid Biopsy with Dr SwatiJha/Outreach @RFhospital @GianchandaniDr @FederalBankLtd @ChetanMadre @dubey_shub17379 @APCLC_2023 Celebrating #WCLC25 @ShankarAbhishek @Sanjeev_33 @KNJobanputra @dr_udip @IASLC

[Razelle Kurzrock, MD @Dr_R_Kurzrock]

Every cancer patient deserves a complete diagnosis.

[Yakup Ergün @dr_yakupergun]

Encorafenib, Cetuximab, and mFOLFOX6 in BRAF-Mutated Colorectal Cancer

It was presented at #ASCO25 and is worth highlighting again: Encorafenib + Cetuximab + FOLFOX doubled OS
https://t.co/Y3NfyreaOW

[Wafik S. El-Deiry, MD, PhD, FACP @weldeiry]

Outstanding international @WIN_Consortium MTB with discussion of difficult cases of glioblastoma &amp; breast cancer including with brain metastases &amp; various driver molecular alterations that are amenable to targeted therapy combinations @Dr_R_Kurzrock @SewantiLimaye @WIN_Consortium

[Razelle Kurzrock, MD @Dr_R_Kurzrock]

Amazing international WIN MTB. Cases presented today by Sewanti Limaye, MD— leading precision oncologist from India.

All under the leadership of Wafik El Deiry.

Bringing experts from around the globe together to help patients.
@weldeiry @SewantiLimaye